K. Christopher Garcia
Founder
Surrozen
Surrozen uses a proprietary antibody‑engineering platform to create multifunctional antibodies that precisely modulate the Wnt signaling pathway and additional ocular disease pathways. These biologics are designed to promote tissue repair, vascular stability, and stem‑cell renewal in the eye, aiming to improve and restore vision for ophthalmic diseases with high unmet need.
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Raised to date
$175MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Claudia Janda
Founder
Hans Clevers
Founder
Roel Nusse
Founder
Calvin Kuo
Founder
Product
Problem
Many ophthalmic diseases, such as advanced retinal degenerations and vascular eye disorders, lack therapies that can restore lost vision because current treatments only address symptoms and do not promote tissue repair or regeneration.
Solution
Surrozen applies its proprietary antibody‑engineering platform to create multifunctional antibodies that precisely modulate the Wnt signaling pathway—a central regulator of tissue renewal and vascular integrity. By targeting Wnt alongside additional disease‑relevant pathways, these antibodies aim to stimulate endogenous repair mechanisms in the eye, potentially improving and restoring visual function. The platform enables the discovery of candidates with combined mechanisms of action, positioning them as best‑in‑class therapies for ophthalmic conditions with high unmet medical need. Surrozen’s pipeline focuses on delivering these next‑generation biologics through clinical development to bring regenerative eye treatments to patients.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing ophthalmic therapeutics, as well as ophthalmologists and retinal specialists seeking regenerative treatment options for patients with advanced eye diseases.
Features
- Proprietary antibody‑engineering platform that designs multifunctional antibodies capable of simultaneous Wnt pathway modulation and engagement of other ocular disease pathways
- Precise control of Wnt signaling to promote stem‑cell renewal, tissue repair, and vascular stability in the retina and other ocular tissues
- Engineered antibodies optimized for ocular delivery, stability, and safety in the eye environment
- Candidate pipeline targeting high‑unmet‑need ophthalmic diseases, with preclinical data indicating best‑in‑class efficacy potential
- Integrated discovery workflow that leverages deep biological insight into Wnt biology to accelerate therapeutic development